SCHEMBL14340919

SCHEMBL14340919

COC(=O)c1ccccc1NC(=O)/C=C(\C)c1ccc(Br)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 7/20 0.51
TSHR P16473 2/20 0.49
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 4/20 0.45
GAA P10253 4/20 0.45
HSD17B10 Q99714 3/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
ALOX15 P16050 1/20 0.45
THRB P10828 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
PPARG P37231 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8802578 0.82 TSHR (0.67) HPGDSMN1; SMN2ALDH1A1TSHRKMT2A
SCHEMBL6791361 0.79 LMNA (0.49) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL3071834 0.78 LMNA (0.74) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL14340918 0.74 HPGD (0.42) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL6783383 0.74 LTB4R (0.62) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL6782877 0.74 HPGD (0.54) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL6785118 0.74 LMNA (0.54) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL6786460 0.74 TERT (0.53) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL6785403 0.74 TERT (0.53) LMNAHPGDHTTSMN1; SMN2ALDH1A1
SCHEMBL14340922 0.73 CES2 (0.48) LMNAHPGDSMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281969-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-06 US disclosed
US-20070281969-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281969-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment GPR119, FFAR1, HCAR1 LMNA 1044/4885HPGD 180/4885HTT 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.